NASDAQ:ORTX - Orchard Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.00
  • Forecasted Upside: 1,856.52 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.46
▼ -0.01 (-2.13%)

This chart shows the closing price for ORTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Orchard Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORTX

Analyst Price Target is $9.00
▲ +1,856.52% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Orchard Therapeutics in the last 3 months. The average price target is $9.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,856.52% upside from the last price of $0.46.

This chart shows the closing price for ORTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Orchard Therapeutics. This rating has held steady since March 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022BarclaysLower Price Target$6.00 ➝ $4.00High
4/1/2022Sumitomo Mitsui Financial GroupReiterated RatingOutperform ➝ NeutralMedium
3/31/2022Stifel NicolausLower Price Target$12.00 ➝ $5.00Medium
3/31/2022CowenDowngradeOutperform ➝ Market PerformHigh
2/11/2022Stifel NicolausReiterated RatingBuyLow
12/30/2021Cantor FitzgeraldInitiated CoverageOverweight$12.00 ➝ $9.00High
11/16/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
11/5/2021OppenheimerLower Price TargetOutperform$15.00 ➝ $13.00Medium
10/18/2021Cantor FitzgeraldReiterated RatingOverweightMedium
8/18/2021JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
6/30/2021JPMorgan Chase & Co.Lower Price TargetOverweight$15.00 ➝ $14.00High
6/30/2021Cantor FitzgeraldLower Price TargetOverweight$17.00 ➝ $12.00High
5/17/2021OppenheimerReiterated RatingBuy$17.00Low
3/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight$14.00 ➝ $15.00N/A
3/2/2021JPMorgan Chase & Co.Boost Price TargetOverweight$14.00 ➝ $15.00High
3/1/2021Stifel NicolausInitiated CoverageBuy$12.00High
1/6/2021Cantor FitzgeraldInitiated CoverageOverweight$16.00N/A
9/14/2020OppenheimerLower Price TargetOutperform$26.00 ➝ $16.00High
6/1/2020OppenheimerInitiated CoverageBuyHigh
5/22/2020JPMorgan Chase & Co.Lower Price TargetOverweight$26.00 ➝ $17.00Medium
5/7/2020OppenheimerReiterated RatingBuy$26.00High
4/1/2020OppenheimerLower Price TargetOutperform$29.00 ➝ $28.00Medium
12/2/2019CowenReiterated RatingBuy$28.00Medium
11/6/2019CowenReiterated RatingBuy$28.00High
9/17/2019GuggenheimInitiated CoverageBuy$31.00Low
9/15/2019CowenInitiated CoverageBuy$27.00Medium
9/5/2019BarclaysInitiated CoverageOverweight$21.00Low
9/4/2019CowenReiterated RatingBuy$27.00Low
8/29/2019OppenheimerInitiated CoverageOutperform$26.00High
3/22/2019WedbushReiterated RatingOutperform$25.00High
12/17/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$18.00 ➝ $21.00High
12/2/2018WedbushInitiated CoverageOutperform$25.00 ➝ $16.80Medium
11/26/2018WedbushInitiated CoverageOutperform ➝ Outperform$25.00 ➝ $25.00Medium
11/26/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$25.00Medium
11/26/2018CowenInitiated CoverageOutperform$27.00Medium
11/26/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$18.00Medium
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/27/2021
  • 3 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
12/27/2021
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/25/2022
  • 1 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
3/27/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
4/26/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
5/26/2022

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Orchard Therapeutics logo
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $0.46
Low: $0.45
High: $0.48

50 Day Range

MA: $0.63
Low: $0.42
High: $0.85

52 Week Range

Now: $0.46
Low: $0.41
High: $5.54

Volume

388,971 shs

Average Volume

606,386 shs

Market Capitalization

$57.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Orchard Therapeutics?

The following Wall Street sell-side analysts have issued reports on Orchard Therapeutics in the last twelve months: Barclays PLC, Cantor Fitzgerald, Cowen Inc, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Stifel Nicolaus, Sumitomo Mitsui Financial Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for ORTX.

What is the current price target for Orchard Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Orchard Therapeutics in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 1,856.5%.
View the latest price targets for ORTX.

What is the current consensus analyst rating for Orchard Therapeutics?

Orchard Therapeutics currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ORTX, but not buy more shares or sell existing shares.
View the latest ratings for ORTX.

How do I contact Orchard Therapeutics' investor relations team?

Orchard Therapeutics' physical mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company's listed phone number is 442038088286. The official website for Orchard Therapeutics is www.orchard-tx.com. Learn More about contacing Orchard Therapeutics investor relations.